NTHI

8-K/A - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

4/A - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

DENVER, Aug. 18, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) has just added another potentially important element to an already potent story: its CEO, Amir Heshmatpour, is continuing to buy shares on the open market. According to the Form 4 transaction information provided by the company’s latest filing, Heshmatpour purchased 12,000 NTHI shares on August 14 at an average price of $3.7883 and another 3,000 shares on August 17 at an average price of $4.3733. Combined, the 15,000 shares represent roughly $58,600 of additional open-market buying, at a weighted average price of approximately $3.91 per share. That distinction matters. Insider open-

4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

DENVER, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Here are today’s catalysts reshaping the market narrative. NeOnc Technologies Holdings: Phase 2a Data Could Just Be the Beginning NeOnc (NASDAQ:NTHI) has produced the kind of clinical update that can force investors to reconsider an entire biotech story. On August 12, the company reported topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma, including a 48.9% six-month progression-free survival rate, versus a prespecified 20% historical benchmark. Median overall survival was reported at 26.09 months, with 86.7% of patients alive at six months, 60.9% at 12 months and 54.1% at 24 months. Five of 24 patients rema

DENVER, Aug. 17, 2026 (GLOBE NEWSWIRE) -- There is a tendency to think of a Nasdaq listing as simply a better place for a stock to trade. For NeOnc Technologies Holdings (NASDAQ:NTHI), however, the Nasdaq Global Market listing has become considerably more interesting following NeOnc’s Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma. The company reported a six-month progression-free survival rate of 48.9%, nearly 2.5 times the 20% historical benchmark, with a reported p-value of 0.0047. NeOnc also reported median overall survival of approximately 26.1 months, while six-, 12- and 24-month overall-survival rates were approximately 86.7%, 60.9% and 54.1%, respectively.

DENVER, Aug. 14, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Today’s stock market coverage illustrates two very different kinds of momentum. NeOnc (NASDAQ:NTHI), MDxHealth (NASDAQ:MDXH), and Capricor Therapeutics (NASDAQ:CAPR) are fundamentally driven healthcare stories, where clinical data, regulatory decisions, diagnostics adoption and cash runway determine whether today's enthusiasm can become a durable rerating, while Onfolio Holdings (NASDAQ:ONFO) is a structure-sensitive short squeeze. NeOnc Technologies Holdings: Phase 2a Data Put NEO100 at the Center of the Story NeOnc (NASDAQ:NTHI) is the clear fundamental headline among this group. The company’s NEO100 Phase 2a readout

8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

DENVER, Aug. 12, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com)- The market is serving up several very different stories converging into one high-energy trading session. Rocky Mountain Chocolate Factory (NASDAQ:RMCF) is suddenly in play after disclosing that its board is exploring strategic alternatives that could include a sale, merger or going-private transaction. NeOnc Technologies Holdings (NASDAQ:NTHI) delivered a major clinical catalyst with NEO100 beating the six-month progression-free-survival benchmark by nearly 2.5 times. Meanwhile, Boxlight (NASDAQ:BOXL) is trying to buy itself additional financial runway, while OFA Group (NASDAQ:OFAL) is in the mix after its recent 1-for-10 rever

DALLAS, Aug. 12, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings (NASDAQ:NTHI) has delivered the kind of clinical update that can change the conversation around a small biotechnology company: its Phase 2a study of intranasal NEO100 in recurrent IDH1-mutant high-grade glioma met its primary endpoint, with six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for standard of care, producing a reported p-value of 0.0047. The company also reported median overall survival of 26.09 months, with 86.7% of patients alive at six months, 60.9% at 12 months and 54.1% at 24 months. Just as important from a patient perspective, five of the 24 patients remained on treatme

8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

Company to request a Type B meeting with the FDA to align on a registrational path in a setting with no approved targeted therapy — Study met its primary endpoint: six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for standard of care (p = 0.0047) — Median overall survival of 26.09 months; 86.7% of patients alive at six months — Five of 24 patients remain on treatment, with one partial response ongoing beyond 114 days — No major toxicities reported across the cohort; adverse events predominantly low-grade — Company to host investor conference call and webcast today at 8:30 a.m. Eastern TimeCALABASAS, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- NeOnc Techn

DENVER, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Planet Green Holdings (NYSEAMERICAN:PLAG), NeOnc Technologies (NASDAQ:NTHI), and Quantum Corporation (NASDAQ:QMCO) made nice runs since our midday coverage. While AbCellera Biologics (NASDAQ:ABCL) and Bank of America are among the notable names reaching new 52-week highs Tuesday. However, among the group, NeOnc may be heading into Wednesday with the most clearly defined and potentially binary catalyst: topline Phase 2a data for its brain-cancer program. NeOnc: Wednesday’s Brain-Cancer Data Could be the Biggest Catalyst of the Group NeOnc Technologies (NASDAQ:NTHI) is heading into Wednesday with a clinical catalyst that could sharply alter the ma

DENVER, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Quantum Corporation (NASDAQ:QMCO), NIQ Global Intelligence (NYSE:NIQ), Fermi (NASDAQ:FRMI), and NeOnc Technologies (NASDAQ:NTHI) are delivering a powerful mix of catalysts from very different corners of the market. Several are moving on developments that could reshape their stories well beyond a single trading session, while the market continues to reward companies that can connect themselves to some of the biggest themes of 2026, like NeOnc, which heads into Wednesday with perhaps the most binary catalyst of the group: topline Phase 2a brain-cancer data that could materially alter how investors value its NEO100 program. NeOnc: Wednesday's brain-c

DENVER, Aug. 11, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies (NASDAQ:NTHI) is heading into Wednesday with the kind of setup that can put a clinical-stage biotech squarely on the market’s radar: a stock trading near its 52-week low, a relatively small trading float, more than 500,000 shares reported short, three Wall Street Buy ratings and a long-awaited brain-cancer data readout. The question is whether the clinical data can justify the attention. NeOnc is scheduled to release topline Phase 2a results from its NEO100-01 trial at 8:30 a.m. ET on Wednesday, August 12, evaluating intranasal NEO100 in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. The compa

8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

DENVER, Aug. 10, 2026 (GLOBE NEWSWIRE) -- (247mnn.com) — Today's market is being driven by a potent combination of corporate catalysts, clinical readouts and investor anticipation, with Socket Mobile (NASDAQ:SCKT) emerging as one of the session's standout movers while biotech names AbCellera Biologics (NASDAQ:ABCL), Silence Therapeutics (NASDAQ:SLN) and NeOnc Technologies (NASDAQ:NTHI) command attention around major clinical milestones. Socket Mobile: The Breakout Stock with a New Distribution Engine Socket Mobile (NASDAQ:SCKT) is kicking off the week as one of the market's most explosive small-cap movers after announcing a strategic partnership with 3Eye Technologies, a value-added dist

DENVER, Aug. 10, 2026 (GLOBE NEWSWIRE) -- (247mnn.com) –NeOnc Technologies (NASDAQ:NTHI) is heading into one of its most closely watched weeks of 2026, with the clinical-stage CNS oncology company scheduled to unveil topline Phase 2a results for NEO100 on Wednesday, August 12, putting the spotlight squarely on data from the fully enrolled study evaluating intranasal NEO100 in patients with recurrent IDH1-mutant high-grade glioma. For a small-cap biotechnology company, a clinical readout of this significance can become a powerful near-term catalyst, particularly when investors are already positioning around a defined event. The company is developing NEO100™, its proprietary formulation of

10-Q - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

CALABASAS, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments for central nervous system cancers, today announced financial results for the second quarter ended June 30, 2026, highlighted recent clinical and regulatory progress across its NEO100 and NEO212 programs, and confirmed that topline results from its fully enrolled Phase 2a NEO100 study will be presented on August 12, 2026. Amir Heshmatpour, Executive Chairman, President and Chief Executive Officer, commented: "The second quarter positioned NeOnc for an important period of clinical execut

CALABASAS, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it will host an investor conference call and webcast on Wednesday, August 12, 2026, at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. During the call, members of the NeOnc management team will present topline results from the Phase 2a portion of the NEO100-01 clinical trial, an open-label study of intranasal NEO100™, the Company’s proprietary formulation of purified perillyl alcohol, in patients with recurrent or pr